RePORT ⟩ RePORTER

Skip Navigation Links

Search Results

Project Details

Vaccine and Treatment Evaluation Unit: Phase I Trial of Filovirus Vaccine

Project Number272201300018I-3-27200006-1

Contact PI/Project LeaderSPEARMAN, PAUL

Awardee OrganizationEMORY UNIVERSITY

Description

Abstract Text

The Vaccine and Treatment Evaluation Units (VTEUs) are a consortium of individual contracts within academic centers and organizations that provide a ready resource for the design and conduct of clinical trials to evaluate promising vaccines and treatments for infectious disease. Investigations of novel product delivery systems and routes of delivery may also be conducted. In general, products will be evaluated in normal healthy populations; however, access to special populations is also available.

Public Health Relevance Statement

Data not available.

NIH Spending Category

Biodefense Biotechnology Clinical Research Clinical Trials and Supportive Activities Emerging Infectious Diseases Immunization Infectious Diseases Prevention Rare Diseases Vaccine Related

Project Terms

Conduct Clinical TrialsContractsEbola virusEvaluationFiloviridaeFilovirusFrankfurt-Marburg Syndrome VirusIndividualInvestigationPopulationResourcesRouteSystemVaccinesdesigninfectious disease treatmentnamed groupnovelphase I trial

Details

Contact PI/ Project Leader

Name

SPEARMAN, PAUL

Title

Contact

Other PIs

Not Applicable

Program Official

Name

Contact

Email not available

Organization

Name

EMORY UNIVERSITY

City

ATLANTA

Country

UNITED STATES (US)

Department Type

Unavailable

Organization Type

Domestic Higher Education

State Code

Congressional District

Other Information

Opportunity Number

Study Section

Fiscal Year

2017

Award Notice Date

Administering Institutes or Centers

National Institute of Allergy and Infectious Diseases

CFDA Code

DUNS Number

066469933

UEI

S352L5PJLMP8

Project Start Date

01-July-2015

Project End Date

01-July-2019

Budget Start Date

Budget End Date

Project Funding Information for 2017

Total Funding

$327,462

Direct Costs

Indirect Costs

Year	Funding IC	FY Total Cost by IC
2017	National Institute of Allergy and Infectious Diseases	$327,462

NIH Categorical SpendingClick here for more information on NIH Categorical Spending

Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	$327,462	Biotechnology; Clinical Research; Clinical Trials and Supportive Activities; Emerging Infectious Diseases; Immunization; Infectious Diseases; Prevention; Rare Diseases; Vaccine Related

Sub Projects

No Sub Projects information available for 272201300018I-3-27200006-1

Publications

Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.

No Publications available for 272201300018I-3-27200006-1

Patents

No Patents information available for 272201300018I-3-27200006-1

Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 272201300018I-3-27200006-1

Clinical Studies

No Clinical Studies information available for 272201300018I-3-27200006-1

News and More

Section Menu